ArticleRheumatology and therapy2022

Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.

Dalton Sholter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.